Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients
Neuro-Oncology · 01.01.2026 · 28 (1) · 130-142
DOI: 10.1093/neuonc/noaf204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 06.09.2025. Verfasst von Ju-Hee Oh und 25 weiteren Autor:innen. Beteiligte Einrichtung: Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Brain Neoplasms, Glioma, Cefazolin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MIT, Mayo Physical Sciences Center for Drug Distribution, Efficacy in Brain Tumors.
Abstract (Originalsprache)
Background
Disruption of the blood–brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs.
Methods
Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning. Cefazolin and levetiracetam were administered prior to skin incision, and serial plasma and image-registered tumor samples were collected during the operation. Drug levels were measured by LC-MS/MS, tissue drug levels were corrected for residual blood, and tumor-to-plasma concentration ratios were calculated. Intraoperative microdialysis was performed in a subset of patients to measure the same two drugs.
Results
Tumor (n = 125) and plasma (n = 261) samples were available for analysis from 42 operative cases. Across all samples, the tumor-to-plasma ratio was significantly lower for cefazolin (marginal mean [MM]: 0.15, 95% CI: 0.11–0.19) as compared to levetiracetam (MM: 0.70, 95% CI: 0.64–0.75; P < .001). When compared between contrast-enhancing and non-enhancing regions, tumor-to-plasma ratios for cefazolin varied by 4.4-fold (0.27, 95% CI: 0.20–0.35 vs. 0.06, 95% CI: 0.04–0.08, respectively; P < .001), and varied for levetiracetam by 1.4-fold (0.88, 95% CI: 0.78–0.97 vs. 0.61, 95% CI: 0.55–0.66, respectively; P < .001). These results were confirmed with the intra-operative microdialysis and a population pharmacokinetic analysis.
Conclusions
This study demonstrates significant inter- and intra-tumoral heterogeneity in drug delivery for both levetiracetam and cefazolin within high-grade brain tumors that is not necessarily predicted by clinical MR imaging and may reflect tumor-induced changes in both perfusion and BBB integrity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- Department of Neurological Surgery, Mayo Clinic, Rochester, MN, USA.
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Cecile Riviere-Cazaux, Timothy J Kaufmann, Caterina Giannini, Evanthia Galanis, Jann N Sarkaria
Förderung
- MIT
- Mayo Physical Sciences Center for Drug Distribution
- Efficacy in Brain Tumors
- NCI NIH HHS
- National Brain Tumor Society
- NINDS NIH HHS
- William H. Donner Professorship
- Mayo Clinic
Zitieren
APA
Oh, J. H., Reed, S. K., Riviere-Cazaux, C., Kim, M., Mladek, A. C., Illamola, S. M., Zhang, W., Vaubel, R. A., Caron, A., Regan, M. S., Birnbaum, A. K., Mohammad, A., Zhang, W., Dixon, J. G., Kaufmann, T. J., Hu, L. S., Ma, D. J., Kizilbash, S., Agar, N. Y. R., …, & Sarkaria, J. N. (2026). Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients. Neuro-Oncology, 28(1), 130-142. https://doi.org/10.1093/neuonc/noaf204
Vancouver
Oh JH, Reed SK, Riviere-Cazaux C, Kim M, Mladek AC, Illamola SM, et al. Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients. Neuro-Oncology. 2026;28(1):130-142. doi:10.1093/neuonc/noaf204
BibTeX
@article{Oh2026,
author = {Oh, Ju-Hee and Reed, Sarah K and Riviere-Cazaux, Cecile and Kim, Minjee and Mladek, Ann C and Illamola, Silvia M and Zhang, Wenjuan and Vaubel, Rachael A and Caron, Alissa and Regan, Michael S and Birnbaum, Angela K and Mohammad, Afroz and Zhang, Wenqiu and Dixon, Jesse G and Kaufmann, Timothy J and Hu, Leland S and Ma, Daniel J and Kizilbash, Sani and Agar, Nathalie Y R and Giannini, Caterina and Geyer, Susan M and Parney, Ian F and Galanis, Evanthia and Burns, Terry C and Elmquist, William F and Sarkaria, Jann N},
title = {Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {1},
pages = {130--142},
doi = {10.1093/neuonc/noaf204}
}
EUVIMED